ImmuneMed’s hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment,

ImmuneMed carried forward with the Phase 2 clinical trial after analyzing the results of Phase 1 study and compassionate use of hzVSF-v13 against …, ImmuneMed carried forward with the Phase 2 clinical trial after analyzing the results of Phase 1 study and compassionate use of hzVSF-v13 against …, Read More

Scroll to Top